HDAC9 and prostate carcinoma: Specifically, our laboratory has demonstrated that the class I HDAC inhibitor entinostat suppresses Treg cell function, enhances immune responses, and increases the antitumor effect of immunotherapies in preclinical models of kidney and prostate cancer [14, 15, 16, 17].